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Extensiveinﬁltrationofthesurroundinghealthybraintissueisacardinalfeatureofglioblastomas,highlylethalbraintumors.Deep
inﬁltration by the glioblastoma cells renders complete surgical excision diﬃcult and contemporary adjuvant therapies have had
littleimpactonlong-termsurvival.Thus,deepinﬁltrationandresistancetoirradiationandchemotherapyremainamajorcauseof
patient mortality. Modern therapies speciﬁcally targeted to this unique aspect of glioblastoma cell biology hold signiﬁcant promise
to substantially improve survival rates for glioblastoma patients. In the present paper, we focus on the role of adhesion signaling
molecules and the actin cytoskeleton in the mesenchymal mode of motility that characterizes invading glioblastoma cells. We then
review current approaches to targeting these elements of the glioblastoma cell migration machinery and discuss other aspects of
cell migration that may improve the treatment of inﬁltrating glioblastoma.
1.Introduction
Glioblastomabraintumorsarethemostcommonadultbrain
cancer and have a very poor prognosis. Despite intensive
eﬀorts, there has been little improvement in the ability
to successfully treat these tumors, and a major reason
for this failure is the unique ability of the glioblastoma
cells to extensively spread throughout the surrounding
healthy brain tissue. There is increasing realization that
the molecular regulators of glioblastoma invasion may be
key to the development of new therapeutic approaches [1].
Developments in the ﬁeld of cell migration have led to the
appreciation that invading cancer cells can adopt diﬀerent
modes of cell migration, and the glioblastoma cells appear to
speciﬁcallyuseamesenchymalmodeofcellmigration.Inthe
present paper, we focus on the adhesion signaling networks
and actin cytoskeleton dynamics that are implicated in
mesenchymal migration and discuss how these molecules
represent exciting potential targets for therapeutic arrest of
glioblastoma cell invasion.
1.1. Glioblastoma Survival and Prognosis. Gliomas are a class
of primary tumors that arise in the brain, and the most
common and lethal form is the grade IV glioblastomas
(previously known as glioblastoma multiformae) [2]. While
brain cancers generally have lower incidence than other
more prevalent cancers—similar to rates worldwide, brain
cancers accounted for ∼2.5% of cancer deaths in the state
of New South Wales, Australia in 2006—there has been
little improvement in patient survival despite advances in
technology, surgery, and adjuvant therapies over the last two
decades. Patient prognosis is dismal with almost 100% rate
of ﬁnal mortality [3]. The median survival time for patients
with glioblastoma remains only 12–15 months [4, 5], and
the 3% 5-year survival rate is signiﬁcantly worse than the
60% survival rate seen for other brain tumors such as
oligodendroglioma and medulloblastoma [5, 6]. Moreover,
survival rates for glioblastoma stand in stark contrast to the
high survival rates for other more common cancers such as
prostate (88%), breast (88%), colon (63%), and melanoma
(80%) [5].
The low survival rates for glioblastoma are, in part, a
consequence of the extensive inﬁltration of healthy brain
tissue that is a cardinal feature of these tumors. Diﬀuse
inﬁltration throughout the brain makes these tumors refrac-
tory to successful surgical excision, and tumor recurrence2 Journal of Oncology
is almost inevitable, with 90% of patients developing new
lesions within 2-3cm of the original site [7] or at distant
sites in the brain [8]. Notably, despite extensive inﬁltration
of the surrounding healthy brain tissue, the glioblastomas
rarely metastasize outside the brain and the inﬁltration of
the brain tissue is signiﬁcantly determined by interaction
between the glioblastoma cells and the unique extracellu-
lar brain environment. A number of extracellular matrix
(ECM) proteins (such as hyaluron, vitronectin, tenascin-
C, osteopontin, and SPARC) are upregulated at the edge
of the advancing glioblastoma tumor, and this may alter
cell invasion (reviewed in [9]). In addition, glioma cell
adhesion is enhanced in regions of the brain where ECM
proteins are present, such as in the blood vessels, and
it suggested that this may facilitate glioblastoma invasion
[10, 11].
1.2. Glioblastoma Characteristics and Diagnosis. Glioblas-
tomas are characterized histopathologically by diﬀuse inﬁl-
tration, increased cellular proliferation, increased angiogen-
esis, nuclear atypia, and necrosis [2], and tumors with these
characteristics are categorized as a grade IV glioma by the
World Health Organization (WHO) [12]. Glioblastomas
may be tumors of either de novo origin or may develop
from a low grade glioma but are histopathologically indistin-
guishable [13]. However, they have distinct genetic proﬁles,
and there are distinct treatment implications for these two
diﬀerent tumor categories [14].
Primary or de novo glioblastoma accounts for approx-
imately 90% of glioblastoma and is chieﬂy diagnosed in
older patients with a mean age of 62 years [13]. Genetic
changes characteristically associated with primary glioblas-
toma include ampliﬁcation and/or overexpression of Epider-
mal Growth Factor Receptor (EGFR) (∼60%) [15, 16]a n d
Mouse double minute 2 (Mdm2) (a key negative regulator
of the tumor suppressor p53) [17, 18], deletion mutations
of Cyclin-Dependent Kinase inhibitor 2A (CDKN2A, also
known as p16INK4A, a cell cycle regulator) [19], and
inactivating mutations of Phosphatase and Tensin Homolog
Deleted on Chromosome 10 (PTEN) [20, 21]. EGFR and
PTEN gene mutations are likely to play a role in glioblastoma
invasion based on the known interaction between EGFR and
Focal Adhesion Kinase (FAK) to promote cell migration [22]
and the role for PTEN as an inhibitor of cell migration
[23, 24]. The potential role, if any, of the other characteristic
mutations in invasion is presently unknown.
Another group of glioblastomas is known to arise
from previously identiﬁed gliomas, usually developing as
a result of malignant transformation several years after
initial diagnosis of a low grade astrocytoma [25]. This type
of glioblastoma is relatively rare by contrast and occurs
in younger patients with a mean age of 45 years [13].
Given that mutations of the tumor suppressor p53 are
present in two-thirds of low grade astrocytomas, it is not
surprising that p53 is the predominant genetic aberration
in secondary glioblastomas (∼60%) [26–28]. Other less
frequent defects include ampliﬁcation/overexpression of
PlateletDerivedGrowthFactorReceptor(PDGFR,areceptor
tyrosine kinase involved in proliferation, migration, and
angiogenesis), deletion of Retinoblastoma gene (RB), and
loss of heterozygosity at 17p, 19q, and 10q [29, 30]. O6-
methylguanine-DNA methyltransferase (MGMT) is a DNA
repair enzyme that protects cells by removing alkyl groups
from the O6 position of guanine. The activity of MGMT
reduces the cytotoxicity of alkylating chemotherapy agents
(such as temozolomide) and contributes to drug resistance
by reversing the DNA damage induced by such agents
[31], and therefore, MGMT silencing is a favorable marker.
Epigenetic silencing of MGMT by promoter methylation has
been detected in 36% of primary glioblastomas, 75% of
secondary glioblastomas, and 40% of pediatric cases [31, 32]
and confers a better prognosis for both adult and pediatric
patients who receive temozolomide treatment [32–34].
Thebraintumorsareoneofthefewclassesofsolidtumor
observed in both pediatric and adult patient populations.
Interestingly, the trend for incidence of the diﬀerent grades
of brain tumor tends to be reversed in the pediatric popu-
lation with the grade IV glioblastomas being less common
(CBTRUS, 2002–2006). However, the 5-year survival rate for
pediatric patients is only 5–15% [35], and thus the outlook
for children diagnosed with glioblastoma remains poor.
Pediatric glioblastomas have a pattern of genetic modiﬁca-
tions distinct from that in adults. Although overexpression
of the EGFR protein is observed in 40% of grade IV pediatric
gliomas, EGFR gene ampliﬁcation in children is very rare
[36].p53genemutationsareveryfrequent,occurringin33%
of pediatric glioblastomas, and 50% of these patients overex-
press mutant p53 protein [35]. p53 overexpression increases
with tumor grade and is correlated with patient outcome
[37]. Unlike the adult tumors, very little information is
available about RB expression in childhood glioblastoma
astrocytoma [25]. Knowledge of the molecular regulation of
pediatric glioblastoma is signiﬁcantly less than that for the
adult form of the disease, and there is an urgent need to
develop cell culture models derived from pediatric tumor
material to address this imbalance.
2. Mechanisms of Glioblastoma Inﬁltration
Most solid cancers progress to disseminated metastatic
disease, evidenced by secondary tumors arising in sites distal
to the primary tumor. The rarity of glioblastoma spread
outside the brain reﬂects the important interaction between
the glioblastoma cells and the unique brain environment.
Thus, the mechanisms of glioblastoma inﬁltration represent
a potentially speciﬁc target for treating glioblastoma.
2.1. Glioblastomas Use a Mesenchymal Mode of Migration
and Invasion. The use of 3-dimensional (3D) collagen gels,
organotypicbrainslicecultures,andimagingofﬂuorescently
labeled glioblastoma cells in in vivo m o u s em o d e l sh a s
established that glioblastoma cells migrate individually with
a mesenchymal mode of motility [38–40]. This is typiﬁed by
a polarized extension of leading edge membrane processes
in the direction of cell migration. This process is critically
dependent on the regulated formation and disassembly of
transmembrane integrin receptor-mediated adhesions to theJournal of Oncology 3
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Figure 1:Glioblastomacellsfollowthetrackscreatedbyothercellsin3Dcollagengels.U87-MGglioblastomacellswereseededintocollagen
type I gels for 24 hours, and then 24-hour time-lapse imaging was performed to track cell migration. Arrows (↑) indicate a “leading” cell
and a “follower” cell, and arrows heads (∧) indicate the single path that they both follow in the collagen gel.
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Figure 2: Schematic representation of a glioblastoma cell migrating through a 3D ECM. During migration, the cell becomes polarized
with respect to the direction of movement into a leading and a trailing edge. The leading edge is characterized by dynamic membrane
rearrangements and proteolytic breakdown of ECM, enabling the cell to protrude at its front. The trailing edge displays constant disassembly
of mature focal adhesions, therefore promoting dislodgement of the rear. Tight regulation of actin assembly and disassembly is crucial for
migration, controlling cellular protrusion, as well as myosin II-mediated contraction in interplay with myosin II.
extracellular matrix, known as focal adhesions [41]. Char-
acteristically during mesenchymal migration, cells secrete
matrix metalloproteases (MMPs) at the leading edge that
break up extracellular components to create corridors for
migration [41, 42]. In the intact brain the glioblastoma cells
travel along white matter tracks and basement membranes
lining blood vessels [43], and thus, the brain environment
uniquely advantages migration of the glioblastoma cells. In
3D collagen gels we have observed a “leader” glioblastoma
cell that appears to reorganize the collagen and create
a track which subsequent glioblastoma cells then follow
(Figure 1); the ability of glioblastoma cells to reorganize
the extracellular matrix is critical to the ability of the cells
to disseminate throughout the brain [1]. Understanding
how the glioblastoma cells interact with and reorganize
the extracellular environment will provide much needed
new approaches to speciﬁcally targeting glioblastoma. Dur-
ing mesenchymal migration through a 3D matrix, cells
protrude a leading pseudopodium with short-lived actin-
r i c hm e m b r a n ep r o t r u s i o n sa sw e l la sl o n g - l i v e dﬁ n g e r -
like protrusions of up to 50μm length, termed ﬁlopodia
(Figure 2). These structures are followed by focal adhesion
formation at the cell front and subsequent detachment of
adhesive contacts at the rear of the cell [40, 44, 45]. This is
a highly dynamic process with paxillin-containing adhesions
at the base of protrusions that disassemble as new adhesions
formneartheleadingedge—aprocessreferredtoasadhesion
turnover [46]. A hallmark of glioblastoma cell inﬁltration
through a 3D environment is the extension of long, thin
polarized membrane extensions that explore and penetrate
the surrounding environment [38, 39]. Presumably cells
employ this mechanism in vivo to ﬁnd and then travel along4 Journal of Oncology
thewhitemattertractsandendothelialliningofbloodvessels
in the brain.
2.2. Integrin Receptors and Focal Adhesions in Mesenchymal
Migration. There are intensive research eﬀorts currently
underway to try and understand the critical molecular
regulators of mesenchymal migration. Although our under-
standing of this process remains incomplete, it is useful
to understand the present state of play and consider how
this currently and, may in the future, informs therapeutic
approaches to the treatment of glioblastoma. The focal
adhesions (FAs) are points of linkage between the ECM,
the transmembrane integrin receptors, and the internal actin
cytoskeleton. In addition to their role as anchorage points to
the matrix, the FAs also transmit information bidirectionally
between the cell and the external environment [47], and the
regulated formation and disassembly of these sites, is critical
to mesenchymal migration.
Theintegrinreceptorsareheterodimerictransmembrane
complexes consisting of an α and a β subunit [48]. Mammals
utilize 18α and 8β subunits, and combinations of these
subunits create receptors for speciﬁc ECM components
including ﬁbronectins, laminins, and collagens [49–51].
During tumor development, changes in integrin receptor
expression, intracellular control of integrin function, and
signals perceived from integrin receptor ligand binding
inﬂuence the cell’s ability to interact with the environment,
enabling metastatic cells to convert from a sessile, stationary
phenotype to a migratory and invasive phenotype [51, 52].
Although there is some evidence for elevated expression
levels of distinct integrin receptor subunits (αv, β1, and
β3) in cell lines derived from disseminated cancers [53],
there is no subunit expression proﬁle that can function as a
marker of metastasis [54]. However, integrin receptor αvβ3
is highly expressed on the cell surface across a range of
tumor types, including glioblastoma [55]. The αvβ3r e c e p t o r
is an important attachment factor for ECM proteins with
the exposed arginine-glycine-aspartate (RGD) motif such as
ﬁbronectin [56–58]. Much focus has been placed on the role
of the αvβ3 receptor in the angiogenesis that is characteristic
of the highly vascularized glioblastomas [59]. However,
equally important but less emphasized to date is the role of
αvβ3 in mesenchymal cell migration. This receptor is found
in the initial rapidly turned over adhesions (focal complexes)
that form at the migrating cells leading edge [60]a n dm a yb e
important in determining the formation of other adhesion
types in the cell [61]. Given that the αvβ3 receptor is highly
expressed in glioblastoma [62–67] and indeed is a target
of major new therapies (see details below), it is paramount
that trials designed to target this receptor in glioblastoma
consider the role this receptor plays not only in glioblastoma
neo-angiogenesis but also in the invasion of glioblastoma
cells.
2.3. The FAK/Src Signaling Axis in Mesenchymal Migra-
tion. Components of the Focal Adhesion Kinase (FAK)/Src
tyrosine kinase migration signaling network (Figure 3)a r e
upregulated and activated in glioblastoma and a number
of therapeutic approaches targeting these molecules are
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Figure 3: The FAK/Src/Cas signaling network downstream from
integrin receptor engagement. Downstream from this network,
RhoA, Rac1, and Cdc42 induce cytoskeletal changes that regulate
cell migration.
currently under clinical trial. Gliomas express elevated
expressionlevelsofthenonreceptortyrosinekinaseFAK,and
this is particularly true of cells at the invasive margins of
the primary tumor [68]. Moreover, FAK signaling appears
critical to the migration of glioblastoma cells [69, 70].
The proto-oncogene Src tyrosine kinase is a major FAK
interactor; interaction of these two proteins is a vital
determinant of mesenchymal cell migration. Both FAK and
Src have emerged as important targets for the treatment
of glioblastoma [71]; thus below we describe the FAK/Src
signaling axis in mesenchymal migration.
Integrin receptors lack any intrinsic catalytic activity
and instead function by recruiting an array of cytoplasmic
proteins [72] which in turn establishes phosphorylation-
dependent signaling networks. FAK functions as an integrin-
activated “scaﬀold” for the recruitment of signaling proteins
that contain Src homology (SH) domains, SH2, and SH3, to
sites of integrin receptor clustering [73], and is involved in
thedynamicregulationofactinandfocaladhesionstructures
[74]. Genetic ablation of FAK reduces mesenchymal cell
migration [75], and conversely, elevated FAK expression
enhances cell migration in an Src/Fyn-dependent manner
[76, 77]. Not surprisingly therefore, high FAK expression
levels are observed in a range of invasive human tumors [78].
Current models of FAK activation suggest that intramolecu-
lar interactions between FAK domains inhibit the protein’s
enzymatic function, and this inhibition is reversed following
receptor stimulation, leading to FAK autophosphorylation at
tyrosine 397 [79]. This exposes binding sites for SH2 and
SH3 domains of Src kinase. Bound Src then catalyzes the
phosphorylation of tyrosines 576 and 577 in the activation
loop of FAK, conferring full catalytic activity to the enzyme.
FAK activation and/or phosphorylation is critical for pro-
moting cell migration [23, 24, 73, 80, 81]. Activated FAK
binds and phosphorylates a number of signaling proteins byJournal of Oncology 5
recognizing SH2 and SH3 domains including Shc [82], the
p85 subunit of phosphatidylinositol 3-kinase (PI3K) [83],
the Rho GTPase activating protein GRAF [84], growth factor
receptorboundprotein2(Grb2),paxillin[85],andmembers
of the Cas family of adhesion docking proteins [77, 86–88].
Importantly, a second FAK subfamily member, Related
Adhesion Focal Tyrosine Kinase (RAFTK)/Proline-rich tyro-
sine kinase (Pyk2), may also play a role in glioblastoma
inﬁltration. These two proteins have overlapping functions
and downstream partners, and while FAK is ubiquitously
expressed, RAFTK/Pyk2 has a more restricted expression
and is predominantly seen in brain and hematopoietic
cells. RAFTK/Pyk2 is correlated with increased malignancy
in glioblastoma [89], and overexpression accelerates cell
invasion in breast cancer [90]. Critically, both FAK and
RAFTK/Pyk2 knockdowns enhanced survival in a mouse
model of orthotopic glioma xenografts [91]. Thus both FAK
and RAFTK/Pyk represent important targets for arresting
glioblastoma inﬁltration.
Src is similarly activated in numerous tumor types
[92], and the kinase activity of this protein is required
for focal adhesion turnover during migration [93]. Among
proteins of the adhesome, Src displays the greatest number
of interactions with other molecules in that network [72]
and thus, presumably, is a key regulator of the focal adhesion
signaling networks. Multiprotein complexes consisting of
interactions between active FAK, Src, and adaptor molecules
such as paxillin and the Cas family of proteins are important
determinants of downstream signaling to promote cell
migration. Within these complexes, phosphorylation of
paxillin and the Cas proteins by Src induces cell migration
[94–97]. Indeed, it is suggested that FAK serves as a scaﬀold
for Src and the Cas protein p130Cas and that this molecular
interaction results in sustained Src signaling [87, 98, 99].
Via this activity of FAK and Src and their target
molecules, including those of the Cas family of proteins and
paxillin, a signaling network is established that culminates in
the activation of GTPase proteins, such as Rac. In turn, this
determines the dynamic state of the actin cytoskeleton that is
essential to the morphological progression of mesenchymal
cell migration [77, 100, 101]. The small GTPase Rac is a
speciﬁc regulator of mesenchymal cell migration [102] that
stimulates the branching of short actin ﬁlaments at the
cell’s leading edge. The newly polymerized short ﬁlaments
push on the membrane to form the leading edge protrusion
that is a characteristic feature of mesenchymal cells. By
employment of such phosphorylation cascades, the cell is
responsive to extracellular cues in a tightly regulated manner
byreorganizationoftheactincytoskeleton,resultingineither
cell migration or adhesion [77, 103–105].
2.4. Actin Function and Regulation During Mesenchymal
Migration. Cells migrating with a mesenchymal phenotype
have a characteristic array of polymerized actin, displaying
short, branched ﬁlaments at the leading edge and longer
tension-bearing ﬁlaments in the cytoplasm known as stress
ﬁbers [40]. Directed movement is facilitated by complemen-
tary eﬀects of the FA (sensing and attaching to ECM) and the
actin cytoskeleton (mediating cell shape). Actin ﬁlaments are
physically linked to the FA through molecules, such as talin
and vinculin that contain both integrin and actin binding
domains.WhenconnectedtotheFA,thestressﬁbersbecome
contractile due to the integration of myosin II [106–109],
and the contraction of such actomyosin ﬁlaments is the basis
for cell locomotion. Myosin II contraction is achieved by
phosphorylation of the myosin light chain via the Ca+2-a n d
calmodulin-dependent myosin light chain kinase (MLCK)
[110]. Desphosphorylation of the myosin light chain by the
MLC phosphatase (MLCP) results in myosin II inactivation.
The eﬀects of MLCP can be countered by phosphorylation
mediated by the Rho GTPase eﬀector Rho-kinase [108, 111].
Given the critical role of FA and actin interaction in cell
migration, much research has concentrated on the mecha-
nistic relationship between actin nucleators and FA proteins
in the formation of new actin structures [112]. The actin
nucleationprocessismediated bytheactin-regulatedprotein
2/3 complex (Arp2/3) and activated by the Wiskott-Aldrich
syndrome protein (WASP) and WASP family Verprolin-
homologous (WAVE) family of proteins [112–114]. As a
result of WASP activation, actin polymerization pushes
the plasma membrane forward, leading to ruﬄing and
pseudopodial extension of the leading edge cell membrane
[115, 116]. In 2006, Butler et al. reported that puriﬁed
αvβ3 integrin receptor complexes exhibit enhanced actin
polymerization activity, thus providing evidence to suggest
a direct interaction between actin nucleation and adhesion
sites [117]. Although the focal adhesion protein vinculin
transiently associates with Arp2/3 during cell adhesion to
ﬁbronectin or after epidermal growth factor stimulation
[118], the fact that vinculin-negative cells can still generate
lamellipodia and migrate faster [119, 120] suggests that
vinculin may not be the major adaptor candidate for
integrin-actin signaling. The Arp2/3-WASP complex directly
interacts with FAK, but only at sites where the latter is not
active (not phosphorylated at tyrosine 397), for example, in
mature adhesion structures [121] .T h e s ed a t ag i v er i s et ot h e
conclusion that FAK interaction with Arp2/3 may regulate
the formation of early protrusive lamellipodia [121], and
therefore FAK represents an excellent target for blocking the
migration of glioblastoma cells.
2.5. Rho GTPases and Mesenchymal Cell Migration. The
driving force for cell movement is derived primarily from the
coordinated assembly and disassembly of actin ﬁlaments and
the Rho family GTPases, RhoA, Rac1, and Cdc42 are critical
regulators of this process. Together these enzymes regulate
the organization of actin ﬁlaments and cooperate to control
polarity, protrusion and adhesion during cell movement
[113, 122]. Other Rho GTPases, such as RhoG, RhoD, TC10,
and Rif (RhoF) can also induce actin-based protrusions
at the cell membrane [123–125]. Activity of RhoA, Rac1,
and Cdc42 is associated with distinct populations of actin
ﬁlaments and associated adhesions [126]. Rac1 activation
promotes the formation of precursor adhesions (focal com-
plexes) in the meshwork of actin ﬁlaments at the leading
edge [60] while Cdc42 stimulates small focal complexes at
the tip of thin membrane protrusions, known as ﬁlopodia,
that contain parallel bundles of actin ﬁlaments [115]. RhoA6 Journal of Oncology
activation is associated with the formation of mature focal
adhesions and actin stress ﬁbers [127, 128]. RhoA, Rac1,
and Cdc42 activate WASP proteins and Diaphanous-related
formins (DRFs) that in turn promote actin polymerization.
Importantly, Cdc42 and Rac1 are active at the leading edge
of a migrating cell, where their targets, WAVE/N-WASP,
are located [114]. Rac1 is a key regulator of migration and
localizes to the leading edge of a moving cell where it is
activated by growth factors and integrin-mediated cell adhe-
sion [129, 130]. Rac1 activation is a major target of signaling
throughtheCasfamilyofproteins[101,131,132].Anumber
of studies have indicated that Rac1 is a speciﬁc regulator
of mesenchymal migration, and indeed Rac1-dependent
invasion through a 3D matrix is one of the deﬁning features
of mesenchymal cell migration [41, 102, 133, 134].
Rho proteins can also regulate the actin depolymerizing
factor ADF/coﬁlin, and thus actin nucleation, indirectly
through Rho kinase (ROCK) and p21-activated kinase-1
(PAK-1). RhoA activates ROCK while Cdc42/Rac1 acti-
vates PAK-1/-2/-3. ROCK and PAK in turn phosphorylate
and activate LIM-motif-containing kinase protein (LIMK),
which inactivates coﬁlin and thus the recycling of actin
ﬁlaments at early lamellipodial extensions [113, 135–137].
3. CurrentTherapeutic Approaches to
TargetingInﬁltratingGlioblastoma
The history of treating malignant gliomas dates back over a
century. The ﬁrst surgical operation to treat brain cancer was
reportedin1884butbarelymadeanimprovementonpatient
survival[138].Intheearlytomid1900s,surgeonsperformed
hemispherectomies (surgical removal of a cerebral hemi-
sphere) in a desperate bid to cure patients with glioblastoma,
despite the inevitable consequences of hemiplegia (paralysis
of one side of the body) and hemiparesis (weakness on one
side of the body) [139]. In spite of the high cost of such
a radical treatment, hemispherectomy could not guarantee
full removal of the glioblastoma cells. The subsequent
introduction of radiation therapy prolonged survival by
several months but was still unsuccessful as a long-term
treatment [140]. Finally, chemotherapy was developed, but
although combined chemotherapy and radiation therapy
has signiﬁcantly improved patient survival for various solid
tumors, it is still incapable of curing most glioblastoma
patients in the long term [4].
The standard treatment for newly diagnosed glioblas-
tomas consists of initial surgery to remove as much
of the tumor as possible, followed by radiation therapy
and chemotherapy [141]. Surgical resection, the ﬁrst step,
eradicates as much of the tumor as possible, and studies
have suggested a positive correlation between aggressive
surgical resection and survival [142]. However, in 35–
40% of patients, an attempt at surgical resection is not
an option due to the medical condition of the patient or
more often because of the location of the tumor [143]. In
these cases, patients may resort to stereotactic radiosurgery,
a form of intense and localized radiation therapy. Previ-
ously, standard chemotherapy for both adult and pediatric
glioblastoma patients involved the administration of PVC
(procarbazine,vincristine,andlomustine(CCNU))or,alter-
natively, nitrosourea drugs such as carmustine (BCNU) and
CCNU. More recently, the use of the oral alkylating drug
temozolomide is growing and has become the established
adjuvant standard of care because it has good ability to
cross the blood brain barrier [144] and has proven to be
more beneﬁcial than the traditional chemotherapy agents
[145, 146]. However, despite prolonging the time to pro-
gression, temozolomide does not signiﬁcantly extend overall
survival [147]. This relative lack of success in glioblastoma
treatment throughout history has highlighted the need
to develop new, more eﬀective therapies. One popular
target for therapy is angiogenesis, the process of blood
vessel formation, which is a critical factor in glioblastoma
invasion as well as in other types of cancers [148]. However,
glioblastomas can also incorporate pre-existing vasculature
(known as cooption) as an alternative to forming new
blood vessels (neovascularization) [149]. In vivo imaging
of glioma cell invasion has revealed that the main tumor
mass can grow by cooption [150] and that cooption can
occur in response to angiogenesis inhibition [151]. These
ﬁndings were conﬁrmed in clinical trials of antiangiogenic
agents, whereby a subset of glioblastoma patients treated
with bevacizumab (a Vascular Endothelial Growth Factor-
targeting agent) experienced tumor recurrence with a more
inﬁltrative phenotype that resembled gliomatosis (a type of
malignant glioma with extreme inﬁltrative capacity) [152].
This suggests that blocking angiogenesis may force the cells
into the alternative cooption pathway. Thus, it is critical
to consider other glioblastoma signaling pathways that may
be targeted; below we consider those treatments targeting
molecules that are prominent players in migration.
3.1. Agents That Target Integrin Receptors. Integrin receptors
reported to be upregulated on glioma cells include α3β1,
αvβ1, αvβ3, and αvβ5[ 153] although αvβ3 expression
levels can diﬀer across glioma cell lines [154]. The αvβ3
and αvβ5 receptors are expressed both in endothelial cells
associated with new vasculature and in the glioma tumor
cells [59, 155–157] and increased expression of αvβ3h a s
beenobservedinangiogenicendothelialcellsintumors[158]
and is linked to more aggressive, metastatic breast cancers
[159, 160]. The ability for tumors to grow past a certain
size depends on the ability of the tumor to establish its
own blood supply via the process of angiogenesis [161],
and there has therefore been a major worldwide eﬀort to
target the molecular regulators of angiogenesis. The αvβ3
receptor plays a vital role in angiogenesis [59, 162], and
the agent cilengitide (EMD121974) was synthesized to target
the RGD motif that is recognized by integrin receptors and
thus inhibits αvβ3-dependent adhesion [163]. Notably, this
compound also targets the αvβ5 receptor as both of these
integrins interact with their ligands via speciﬁc RGD motifs
[164]. Importantly, despite originally being designed as an
antiangiogenic therapy, cilengitide has a range of eﬀects
in vitro, including apoptosis and blocking cell adhesion,
migration, and invasion [165]. In preclinical studies using
an orthotopic xenograft mouse model with the humanJournal of Oncology 7
glioblastoma cell line U87MG, cilengitide improved survival
time and inhibited tumor growth and angiogenesis [166].
Furthermore, cilengitide can inhibit glioma cell prolifera-
tion at concentrations as low as 1μg/mL while 50μg/mL
can induce signiﬁcant apoptosis [165]. Cells treated with
cilengitide display disassembly of actin ﬁlaments and loss
of cell-cell contacts [165], dosage-dependent inhibition
of FAK and Src activity [165], and detachment-induced
apoptosis [167, 168]. Phase I and II clinical trials in glioma
patients have had promising results, especially for patients
with hypermethylated MGMT [169, 170], and cilengitide is
currently in Phase III trials in glioblastoma patients treated
with radiation therapy and chemotherapy [171]. The drug
is well tolerated, with patients suﬀering only minimal side
eﬀects [170, 172], and the eﬃcacy is reported to increase
when used in combination with radioimmunotherapy or
temozolomide [62, 173].
3.2. Targeting Cytoplasmic Adhesion Molecules. TAE226 is a
novel small molecule designed to inhibit FAK by blocking
phosphorylation of FAK tyrosine 397. The mechanism of
action is speciﬁc for FAK autophosphorylation as it does
not aﬀect total FAK protein expression and has no eﬀect
on either EGF-induced EGFR phosphorylation or serum-
induced PDGFR phosphorylation [174]. TAE226 has yet
to be tested in clinical trials for glioblastoma, but in
vitro experiments demonstrated increased apoptosis and
decreased angiogenesis [175]. In studies of neuroblastoma,
TAE226 induced apoptosis and G2 cell cycle arrest and
compromises cell viability [176] while in trials in ovarian
cancer, the drug exerts a number of anticancer eﬀects,
including reduction in tumor burden, angiogenesis, and cell
proliferation and improves patient survival [177].
Inhibition of Src activity in either two-dimensional (2D)
or 3D culture models can successfully block glioblastoma
invasion [178, 179]. For example, Src inhibition impairs
pseudopodium formation and actin bursting at the tip of
the pseudopodium [178]. Dasatinib is an orally available
drug that inhibits Src kinase (as well as Eph receptors, Bcr-
Abl, PDGFRβ, and Kit) [180]. This agent has approval by
the Food and Drug Adminstration USA (FDA) for use in
treating leukemias and is presently being tested in a number
of clinical trials for the treatment of glioblastoma. A Phase I
trial is currently investigating the combination with erlotinib
(an EGFR inhibitor), while Phase I/II trials to assess the
use of a dasatinib/radiotherapy/temozolomide regime in
conjunction with adjuvant dasatinib and temozolomide for
newly diagnosed glioblastoma are about to be launched [71].
Preclinical studies of dasatinib have already shown successful
inhibition of Src activity [180], and an additive eﬀect is
observed when combined with radiotherapy or temozolo-
mide [181]. Furthermore, low concentrations of dasatinib
can block proliferation of glioma cells in vitro [180].
Similar to Dasatinib, AZD0530 is also an orally available
drug that inhibits Src. Although still in the preclinical stage
of testing for glioblastoma treatment, AZD0530 has been
found to inhibit both FAK and paxillin phosphorylation
andactivity.Theresultingabrogationofadhesion-dependent
signaling pathways consequently inhibits cell migration
[182]. In other investigations, AZD0530 blocks invasion and
increases the sensitivity of lung cancer cells to radiation
therapy[183],andpatientrecruitmentisinprocessforPhase
II testing in hormone receptor-negative metastatic breast
cancer.
3.3. Regulators of Actin Cytoskeletal Dynamics. The mam-
malian target of rapamycin (mTOR) is a protein kinase
upstream of PI3K/Akt signaling pathway, and activity of this
protein is inhibited by rapamycin. Involved in various signal-
ing pathways implicated in glioblastoma, mTOR plays a role
in a number of cellular processes, including cell proliferation
and growth, angiogenesis [184]. Critically, rapamycin blocks
F-actin organisation and inhibits phosphorylation of FAK,
paxillin, and p130Cas [185]. In preclinical studies, PTEN-
deﬁcient tumors showed enhanced sensitivity to mTOR
inhibitors, and thus the frequency of inactivating PTEN
mutations in glioblastoma suggests that mTOR inhibitors
may be used to successfully treat glioblastoma [20, 186].
mTORinhibitorshavetolerablelevelsoftoxicity,areeﬀective
in reducing the rate of cell proliferation [187], and improve
patient survival rates [188]. Adverse eﬀects reported follow-
ing rapamycin treatment include hypercholesterolemia and
hyperglycemia and, more seriously, the activation of Akt
[187, 188].
4.Exploitingthe UniqueBiology of
InﬁltratingGlioblastoma to Identify
New Treatment Targets
The approaches outlined above highlight the potential—and
insomecases,success—oftargetingadhesionsignalingpath-
ways in the treatment of glioblastoma. The highly unique
behavior exhibited by the glioblastoma cells in response
to the specialized morphology and molecular structure of
the brain suggests that there is considerably more scope
to target these pathways and derive speciﬁc and eﬃcacious
new therapies. Below, we consider some of the adhesion
signaling pathways and mechanisms that might be amenable
to therapeutic exploitation along with some of the envisaged
caveats.
4.1. Further Targeting of Integrin Receptors. Downregulation
ofβ-integrinbyantisenseβ-1mRNAinaratmodelofglioma
caused a signiﬁcant reduction of brain invasion, attributed
either to impaired interaction with the ECM in the brain or
interference with β-1-dependent signaling pathways [189].
Similarly, direct inhibition of integrin by an integrin-speciﬁc
antibody led to a reduced capacity of ovarian tumor cells
to proliferate [190]. Studies of αvβ3 integrins in the brain
have revealed that the activation state of integrins rather
than expression level controls metastasis and angiogenesis
in tumor cells, and this process is highly susceptible to
cues from the brain microenvironment [191]. Thus, the full
potential for therapies targeting integrin receptors in the
treatment of glioblastoma has probably not yet been fully
realized. However, data suggesting that integrin expression8 Journal of Oncology
may also be essential for maintaining cells in an attached
and stationary mode [192] highlight the need for a thorough
understanding of integrin-related pathways.
In recent times, it has become clear that invading and
migrating cancer cells have a range of motility modes at
theirdisposal thatallowsthecellstomigratethroughdistinct
extracellular environments [40, 193–195]. The ability of
certain cancer cells to switch between an amoeboid-type
migration that does not require the action of MMPs versus
a mesenchymal-type MMP-dependent migration mode is,
at least part of, the reason behind the less than hoped
for success using anti-MMP therapies to treat metastatic
cancers [40, 196]. In addition to the diﬀerential require-
ment for MMPs, each migration mode is characterized by
distinct requirements for integrin-mediated interaction with
the ECM; integrin attachment is an essential requirement
for mesenchymal cell but of less signiﬁcance for amoe-
boid motility. The potential for cancer cells to transition
between migration modes has become a confounding factor
when targeting anticancer pharmaceuticals to integrins [67,
197]. As reviewed above, studies to date suggest that the
glioblastoma cells primarily use the mesenchymal motility
mode for invasion and dissemination. Once there is formal
conﬁrmation that glioblastoma cells do not have the capacity
to switch to an amoeboid movement, therapies designed to
block integrin receptor-mediated cell migration are likely
to have signiﬁcant success in blocking dissemination of
glioblastoma.
4.2. Novel Cytoskeletal Targets. The determining role of the
actin cytoskeleton in the morphological and mechanical
properties that are indispensable for mesenchymal cell
migration suggests that the actin ﬁlament system represents
a major potential target for antimesenchymal migration
strategies. However, the ubiquitous expression and vital
contribution of actin to all cells and tissues in the body mean
that nonspeciﬁc disruption of the actin cytoskeleton would
cause unacceptable and life-threatening side eﬀects. A more
useful approach would therefore be to target speciﬁc actin
regulatory molecules that are either restricted in their tissue
distribution or are functionally specialized. For example,
the tropomyosin family of actin-associating proteins has
emergedascriticalregulatorsofcellmigration[95,198–201].
Association of individual tropomyosin isoforms with actin
ﬁlaments is proposed to impart distinct properties of actin
dynamics on the associated ﬁlament [202], and it has been
suggested that this specialization of the actin ﬁlaments may
represent rational targets for chemotherapy [203].
The dynamics of actin ﬁlaments are critical in cellular
processes ranging from cell division to apoptosis and migra-
tion. The dynamics are therefore subject to regulation by a
vast repertoire of actin-regulatory proteins. Actin-regulatory
proteins that modulate actin function in cell migration
include ADF/coﬁlin [204]. Coﬁlin is highly expressed in
glioblastoma tumor cells and is positively correlated with
motility [205, 206]. Furthermore, coﬁlin activity directly
relates to invasiveness and metastasis in mammary tumors
[207]. However, conﬂicting data [208] and the fact that
coﬁlin inhibition is lethal to both normal and tumor cells
[204] necessitate intervention with other components of
the coﬁlin signaling pathway rather than complete coﬁlin
shutdown. In this regard, proteins such as Phospholipase C-
gamma (PLCγ), slingshot (SSH), LIMK, or chronophin may
represent valid targets for anticancer treatment as each of
these molecules is mediator of coﬁlin signaling. Approaches
to inhibit or stabilize these pathway intermediates may sup-
press the pathway activity suﬃciently to derive therapeutic
beneﬁt in the absence of unacceptably high toxicity levels in
nontumor cells.
The Rho GTPases RhoA, Rac1, Cdc42, and Ras indis-
putably control signal transduction pathways that cooperate
to promote cell movement [122]. Given the deﬁning role
of Rac GTPase activity in the mesenchymal mode of cell
migration [209], it seems sensible that approaches targeting
GTPase activity to block glioblastoma cell invasion and
disseminationshouldfocusontheinhibitionofRac1activity
asapriority.Rac1activitycontrolsdenovoactinnucleationat
the periphery of the cell, resulting in lamellipodia extensions
and membrane ruﬄing [115, 210]. In human glioma cells
the suppression of Rac1 activity induces apoptosis [211], a
ﬁnding that raises the important concept that arresting cell
motility pathways may inﬂuence a cancer cell’s apoptotic
response in a way which could be therapeutically exploited
[212]. Indeed, in nontransformed cells there are many
cellularsafeguardstoensurethattheapoptosisprogrammeis
initiated following detachment from the extracellular matrix
[213]. These safeguards are subverted in oncogenically
transformed cells [214, 215] allowing cells to survive the
remodeling and turnover of adhesion sites that accompanies
the progression to an invasive and migratory phenotype.
Correlated to this, increased activation of the PI3K sur-
vival pathway in glioma cells [212] overcomes detachment-
mediated apoptosis as these cells invade and migrate. An
important caveat to the use of Rho GTPase inhibitors is the
essential role they play in many diﬀerent cellular functions
and thus the potential for side eﬀects in otherwise healthy
tissues. Speciﬁc signaling functions of the Rho GTPases
are directed in part by selective interactions with guanine
nucleotide exchange factors that regulate GTPase activity.
Such molecules may therefore represent attractive targets for
drug intervention with fewer side eﬀects [216].
ThePI3Kpathwaycontributestocytoskeletalremodeling
via signaling through the serine/threonine kinase Akt [217].
Importantly, migrating glioma cells show elevated levels of
phosphorylated Akt and its substrate, Glycogen Synthase
Kinase-3 (GSK-3) and phosphorylated Akt, localizes to the
leading edge of migrating glioblastoma cells [212]. PI3K is
activated by receptor tyrosine kinases through Ras, binding
tothep110subunitofPI3K[218,219].Amajorconsequence
of this is the generation of Phosphatidylinositol (3,4,5)-
trisphosphate (PIP3) in the plasma membrane which in turn
acts as second messenger to activate Akt and other proteins.
PIP3 in the inner leaﬂet of the plasma membrane recruits
and activates Akt [220, 221] which results in cell survival,
proliferation (cell number), and/or growth (cell size) [217].
The conversion from PIP3 to Phosphatidylinositol (4,5)-
bisphosphate (PIP2) is catalyzed by several phosphatases.Journal of Oncology 9
SigniﬁcantlythisincludesPTENwhichisatumorsuppressor
protein in glioblastoma and other cancers [20, 222, 223].
PTEN negatively regulates cell migration by downregulating
Rac1 and Cdc42 via its lipid phosphatase activity by decreas-
ing PIP3 levels [224, 225]. Furthermore, PTEN inhibits
cell migration by downregulating FAK and p130Cas phos-
phorylation [24]. Pharmaceuticals that either downregulate
PI3K/PIP2 or stabilize and/or upregulate the expression
of PTEN might therefore decrease the rate of metastasis
in treated cells. An experimental PI3K inhibitor, PX-866
(which is an improved wortmannin analogue), inhibits
tumor cell migration at sub-nanomolar concentrations
[226].
4.3. Approaches to Identifying Relevant Adhesion Signal-
ing Proteins. Given the critical role of migration in the
progression to metastatic, disseminated cancer, there are
increasing numbers of studies taking a global approach to
identifying molecules that are essential regulators of cell
migration. In one example, investigators used an siRNA
screening approach to identify proteins that modulate the
migratory response of a breast epithelial cell line [227].
The investigators took advantage of the recently described
adhesome [72] and restricted their siRNA targets to a
set of “migration and adhesion related” gene targets. The
a d v a n t a g eo fs u c ha na p p r oa c ho v e rg e n e t i cp r o ﬁ l ea n a l y s i si s
that screening for functional outcome concurrently validates
the target. Beyond such functional screens, the wealth of
geneexpressiondatanowavailable[228–230]meansthatitis
possible to identify potential adhesion and migration related
proteins that are diﬀerentially expressed in glioblastoma
and directly test these molecules. Alternatively, we can
use our current knowledge of adhesion signaling pathways
to predict likely candidate molecules. For example, based
on the known interaction of FAK with the Cas family
of proteins and their role in promoting cell migration
it was proposed, and subsequently conﬁrmed, that the
Cas protein Neural precursor cell-expressed, developmen-
tally downregulated 9 (NEDD9), also known as Human
enhancer of ﬁlamentation 1 (HEF1) and Crk-associated
substrate-lymphocyte type (Cas-L), is a speciﬁc regulator
of glioblastoma cell invasion through brain homogenates
[70], and it is now apparent that NEDD9/HEF1/Cas-L
is a critical regulator of Rac-mediated mesenchymal cell
migration [209]. The emerging role of NEDD9/HEF1/Cas-
L as a key regulator of cancer metastasis [202]m e a n s
that this molecule will increasingly be the target of novel
anticancer treatments [231]. No matter which approach is
taken to identify new cytoplasmic adhesion molecules that
areessentialregulatorsofglioblastomainvasionitisvitalthat
each of these molecules is tested using models that faithfully
recapitulate the brain environment, for example, in the form
of orthotopic xenograft mouse models [231] or via the use of
culture models such as the organotypic brain slice cultures
[38, 39].
Finally, we note that the blood-brain barrier (BBB)
constitutes a major hurdle for any systemic chemotherapy
delivery to treat glioblastoma. The BBB protects the brain
by excluding molecules by size and biochemical proper-
ties and generally prevents the translocation of lipophilic
molecules larger than 500Da to the brain [232–234].
However, Temozolomide, an antiglioblastoma drug which
is already in clinical use, can successfully cross the BBB
after oral administration [235, 236]. Thus any approaches
to treat glioblastoma inﬁltration by targeting the molecular
regulators of mesenchymal migration will need to address
this issue. The ﬁeld of drug targeting to the brain is currently
actively under investigation in parallel with our increasing
knowledge of the molecular regulators of mesenchymal
migration. Avenues being pursued range from transient
osmotic BBB disruption, nanoparticle carriers, to direct
injection into the brain parenchyma [232, 234, 237–239].
Thus, we anticipate that combined eﬀorts in these two
researchﬁeldswillfacilitatethederivationofanti-inﬁltration
drugs that are able to cross the BBB and successfully treat
glioblastoma.
5. Conclusion
There is clearly an urgent need to develop new approaches
to treating glioblastoma—the current poor rate of survival
means that even small improvements in therapy have the
potential to signiﬁcantly improve life expectancy and/or
quality of life for patients diagnosed with this tumor. In
the present paper, we have highlighted recent understanding
of the cellular mechanisms that regulate mesenchymal cell
migration that is characteristic of inﬁltrating glioblastoma.
New targeted therapies focusing on the unique cell biology
that facilitates inﬁltration of the brain parenchyma oﬀer
promise to treating patients with glioblastoma. Understand-
ing cell migration is a necessary ﬁrst step in developing
anti-migration pharmaceuticals. It is unlikely that any agent
targeted against inﬁltration will be eﬀective unless used
in combination with therapies that target other aspects
of tumor biology. Current clinical trials generally measure
improvements in time to progression, but overall impact on
long-term survival has been modest. The challenge for the
future is to translate migration and invasion research into
new therapies for use in the clinical setting and to the design
of clinical trials including outcomes and markers that report
successful inhibition of inﬁltration. As our understanding
of the cell machinery that regulates migration continues to
improve apace, the possibility of improved patient outcomes
by pursuing novel targeted therapies moves forward towards
reality.
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